CAR-T Therapies

CTAF

ICER will develop a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. ICER’s report will consider the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM , Novartis) and axicabtagene ciloleucel (YescartaTM, Kite Pharma). Both agents were approved in 2017. Tisagenlecleucel is approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Novartis is also expected to file later this year for a second indication for diffuse large B-cell lymphoma in adults. Axicabtagene ciloleucel is approved for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients.

Date of Review: March 2018

Associated Meetings

March 2, 2018 10am-4pm PT

Preservation Park (Nile Hall)
1233 Preservation Park Way
Oakland CA, 94612

The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.


Key Dates

Associated Materials

07/19/2017

07/19/2017 – 08/04/2017

08/09/2017

08/09/2017 – 08/29/2017

09/07/2017

10/16/2017

10/16/2017

12/19/2017

This draft will be open to public comment until January 24th. Visit our stakeholder engagement page for more information.


12/19/2017

12/19/2017 – 01/24/2018
Public Comments

02/15/2018
Evidence Report

03/02/2018

Public meeting of CTAF.

Meeting Agenda

03/16/2018
Final Evidence Report and Meeting Summary